Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and alpha-phenyl-N-t-butylnitrone: implications for bioactivation by prostaglandin synthetase

Toxicology and Applied Pharmacology
P G WellsS Ali

Abstract

Teratogenicity of the anticonvulsant drug phenytoin is thought to involve its bioactivation by cytochromes P-450 to a reactive arene oxide intermediate. We hypothesized that phenytoin also may be bioactivated to a teratogenic free radical intermediate by another enzymatic system, prostaglandin synthetase. To evaluate the teratogenic contribution of this latter pathway, an irreversible inhibitor of prostaglandin synthetase, acetylsalicylic acid (ASA), 10 mg/kg intraperitoneally (ip), was administered to pregnant CD-1 mice at 9:00 AM on Gestational Days 12 and 13, 2 hr before phenytoin, 65 mg/kg ip. Other groups were pretreated 2 hr prior to phenytoin administration with either the antioxidant caffeic acid or the free radical spin trapping agent alpha-phenyl-N-t-butylnitrone (PBN). Caffeic acid and PBN were given ip in doses that respectively were up to 1.0 to 0.05 molar equivalents to the dose of phenytoin. Dams were killed on Day 19 and the fetuses were assessed for teratologic anomalies. A similar study evaluated the effect of ASA on the in vivo covalent binding of radiolabeled phenytoin administered on Day 12, in which case dams were killed 24 hr later on Day 13. ASA pretreatment produced a 50% reduction in the incidence of f...Continue Reading

References

Aug 1, 1975·The Journal of Pediatrics·J W Hanson, D W Smith
Oct 5, 1985·Lancet·S M StricklerS P Spielberg
Jan 1, 1988·Teratogenesis, Carcinogenesis, and Mutagenesis·M Wong, P G Wells
Nov 1, 1987·American Journal of Medical Genetics·A S GoldmanM Katsumata
Jun 1, 1972·Toxicology and Applied Pharmacology·R D Harbison, B A Becker
Jan 1, 1980·Advances in Prostaglandin and Thromboxane Research·A E AliT E Eling
Sep 24, 1981·The New England Journal of Medicine·S P SpielbergH F Herlong
Jan 1, 1982·Clinical Pharmacokinetics·E Perucca
Apr 15, 1982·Biochemical Pharmacology·C PantarottoR Abbruzzi
Jun 1, 1980·Teratology·R M McClain, L Langhoff
Jun 1, 1978·Environmental Health Perspectives·R D Harbison

❮ Previous
Next ❯

Citations

Feb 16, 1999·Teratology·J Gelineau-van WaesR H Finnell
Jan 1, 1994·Journal of Inherited Metabolic Disease·G K Brown
Jan 1, 1991·Chemico-biological Interactions·B J SmithT E Eling
Oct 1, 1995·Toxicology in Vitro : an International Journal Published in Association with BIBRA·C HarrisG E Eurich
Dec 1, 1992·Seizure : the Journal of the British Epilepsy Association·D F Weaver
Oct 29, 2003·Toxicology Letters·Gian Mario TiboniCarmine Di Ilio
Jan 1, 1992·Epilepsia·M S Yerby
Mar 8, 2005·Drug Metabolism Reviews·Shufeng ZhouYu-Zong Chen
Oct 17, 2006·Basic & Clinical Pharmacology & Toxicology·Faranak AzarbayjaniBengt R Danielsson
Jan 1, 1995·Drug Metabolism Reviews·T I Edeki, D A Brase
Oct 22, 2008·International Review of Neurobiology·Mark S Yerby
May 18, 2016·Korean journal of pediatrics·Eun-Hee Kim, Tae-Sung Ko
Feb 1, 1996·Critical Reviews in Biochemistry and Molecular Biology·P G Wells, L M Winn
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Miki NakajimaTsuyoshi Yokoi
Jun 10, 2011·Acta Neurologica Scandinavica·R Arya, S Gulati
Apr 19, 2005·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Dominique AbelaWilliam S Webster

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.